Cariad Chester

About

Prior to joining TCGX, Cariad was a Managing Director at Aquilo Capital, where he led investments in biotechnology companies developing human therapeutics. Prior to Aquilo Capital, Cariad was a research scientist at Stanford University studying tumor-immune system interactions during cancer progression and treatment. He has authored or co-authored over 20 peer-reviewed manuscripts and presented research at conferences in Canada, the US, and China. Cariad received his B.A. from Swarthmore College, where he double majored in Neuroscience and Comparative Religious Studies. Cariad’s past investments at TCGX include RAPT (acquired by GSK), Vicebio (acquired by Sanofi), Icosavax (acquired by AstraZeneca), Iveric (acquired by Astellas), Gracell (acquired by AstraZeneca), Versanis (acquired by Eli Lilly), Akouos (acquired by Eli Lilly), VectivBio (acquired by Ironwood), Carmot (acquired by Roche), Tourmaline (acquired by Novartis), Upstream Bio (NASDAQ: UPB), and Structure Therapeutics (NASDAQ

Source (opens in a new tab)